Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
06/2000
06/15/2000CA2353620A1 Methods and formulations for reducing circulating antibodies
06/15/2000CA2353415A1 Vitronectin receptor antagonist
06/15/2000CA2352178A1 Phospholipid compositions
06/15/2000CA2351555A1 Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
06/15/2000CA2350767A1 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
06/15/2000CA2326842A1 Micronized eplerenone compositions
06/15/2000CA2319561A1 Peritoneal dialysis solution containing modified icodextrins
06/14/2000EP1008350A1 Stabilised antithrombin III preparation
06/14/2000EP1007735A1 Anti-sense oligonucleotide pharmacological agents
06/14/2000EP1007679A1 Recombinant human erythropoietin with advantageous glycosylation profile
06/14/2000EP1007561A2 Novel conjugates of opioids and endogenous carriers
06/14/2000EP1007552A2 Diagnostics and therapy of epstein-barr virus in autoimmune disorders
06/14/2000EP1007548A1 Tsetse thrombin inhibitor
06/14/2000EP1007545A2 Cyclopeptide derivatives as adhesion inhibitors
06/14/2000EP1007543A1 A method for stimulating red blood cell production
06/14/2000EP1007539A1 Secreted proteins and polynucleotides encoding them
06/14/2000EP1007094A1 Pharmaceutical compositions for freeze drying
06/14/2000EP1007090A1 Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
06/14/2000EP1007089A1 Anticoagulant agents useful in treatment of thrombosis
06/14/2000EP1007078A1 Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
06/14/2000EP1007037A1 Antithrombotic agents
06/14/2000EP0901463B1 Glycerolipidic compounds used for the transfer of an active substance into a target cell
06/14/2000EP0871606B1 New compounds and their compositions having anti-inflammatory and anti-thrombotic activities
06/14/2000CN1053451C Novel peptide compound with therapeutic active in blood coagulation reaction, its prep. and pharmaceutical composition thereof
06/14/2000CN1053377C Viscosity-reducing Chinese medicine capsule for treatment of high blood viscosity disease
06/14/2000CN1053363C Shengxueyin oral liquid
06/14/2000CN1053359C Shengbaisan powder medicine for umbilicus
06/14/2000CN1053351C Oral liquid for hypertension and hyperlipemia and its preparing process
06/13/2000US6074639 Ex vivo expansion of hematopoietic cells using interleukin-3 (IL-3) variant fusion proteins
06/13/2000CA2137072C Conformationally restrained peptide analogs as antiplatelet agents
06/13/2000CA2085878C Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylidene and piperazine compounds and compositions
06/13/2000CA1341024C Benzo-fused cycloalkane and oxa- and thia-, cycloalkane trans-1, 2-diamine derivatives
06/08/2000WO2000032772A2 Erythropoietic compounds
06/08/2000WO2000032750A1 Transgenic circulating endothelial cells
06/08/2000WO2000032632A2 Allo- and auto-reactive t-cell epitopes from rhesus protein and their use
06/08/2000WO2000032590A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
06/08/2000WO2000032584A2 Nonsteroidal antiinflammatories
06/08/2000WO2000032577A2 Substituted benzo[de]isoquinoline-1,3-diones
06/08/2000WO2000032575A1 β-ALANINE DERIVATIVES AS α4 INTEGRIN INHIBITORS
06/08/2000WO2000032574A1 Novel 2-pyridone derivatives, preparation method and therapeutic use
06/08/2000WO2000032570A1 Hydrazine derivatives
06/08/2000WO2000032221A2 Promotion or inhibition of angiogenesis and cardiovascularization
06/08/2000WO2000032215A1 PGC-1, A NOVEL BROWN FAT PPARη COACTIVATOR
06/08/2000WO2000032189A1 Celecoxib compositions
06/08/2000WO2000032188A2 Use of amtolmetin guacyl as an antiinflammatory drug
06/08/2000WO2000032177A2 Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections
06/08/2000WO2000032175A2 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
06/08/2000WO2000016760A3 New use of prostaglandin e2 antagonists
06/08/2000WO2000012481A3 Indazole derivatives with 5-ht2 receptor activity________________
06/08/2000WO2000009086A3 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
06/08/2000WO1999024076A9 Salicylate derivatized therapeutic and diagnostic agents
06/08/2000CA2634658A1 Use of amtolmetin guacyl for the production of anti-inflammatory drugs for intestinal inflammations
06/08/2000CA2352538A1 Erythropoietic compounds
06/08/2000CA2352367A1 Nonsteroidal antiinflammatories
06/08/2000CA2352205A1 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
06/08/2000CA2352045A1 Substituted benzo[de]isoquinoline-1,3-diones
06/08/2000CA2351671A1 Transgenic circulating endothelial cells
06/08/2000CA2351321A1 Hydrazine derivatives
06/08/2000CA2350597A1 Methods and compositions for restoring conformational stability of a protein of the p53 family
06/08/2000CA2347835A1 Promotion or inhibition of angiogenesis and cardiovascularization
06/08/2000CA2347701A1 .beta.-alanine derivatives as .alpha.4 integrin inhibitors
06/07/2000EP1006182A2 Polypeptide fragments of factor VIIIC, corresponding probes and DNA sequences and DNA constructs
06/07/2000EP1005552A1 Member of the hematopoietin receptor superfamily
06/07/2000EP1005551A2 Tissue factor pathway inhibitor-3
06/07/2000EP1005492A1 Purification of von willebrand factor by cation exchanger chromatography
06/07/2000EP1005341A1 Il-8 receptor antagonists
06/07/2000CN1255924A New process for prepn. of pharmacologically active substance
06/06/2000US6072029 Derivatives of human α1 -antitrypsin and process for their preparation
06/06/2000US6071956 Treatment of tissues to reduce subsequent response to injury
06/06/2000US6071948 Treatment of diseases caused by excessive blood vessel growth
06/06/2000US6071912 Inhibit human factor xa and are therefore useful as pharmacological agents for the treatment of disease-states characterized by thrombotic activity; amino-, oxy- and thia-substituted triazines
06/06/2000US6071723 Inhibitors of human plasmin derived from the Kunitz domains
06/06/2000US6071514 Administering activated protein c and antiplatelet agent and/or anticoagulant
06/04/2000CA2291471A1 Lowering blood levels of lipoprotein(a)
06/02/2000WO2000031263A2 Gtpase associated proteins
06/02/2000WO2000031084A1 Prostaglandin conjugates for treating or preventing bone disease
06/02/2000WO2000031068A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants
06/02/2000WO2000031067A1 Propanoic acid derivatives as integrin inhibitors
06/02/2000WO2000031039A1 Substituted benzo[de]isoquinoline-1,3-diones
06/02/2000WO2000031036A1 Novel naphthalene derivatives
06/02/2000WO2000030677A1 Method of treating viral hemorrhagic fever
06/02/2000WO2000030676A1 Method of treating sickle cell disease and thalassemia
06/02/2000WO2000030668A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
06/02/2000WO2000030665A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
06/02/2000WO2000030657A1 A process for producing an iron-dextran compound
06/02/2000WO2000030622A2 Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
06/02/2000WO2000013703A9 Methods of treating hypertension and compositions for use therein
06/02/2000CA2352585A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
06/02/2000CA2352043A1 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
06/02/2000CA2351679A1 Prostaglandin conjugates for treating or preventing bone disease
06/02/2000CA2351591A1 Method of treating sickle cell disease and thalassemia
06/02/2000CA2351470A1 Method of treating viral hemorrhagic fever
06/02/2000CA2351361A1 Gtpase associated proteins
06/02/2000CA2351348A1 Substituted benzo[de]isoquinoline-1,3-diones
06/02/2000CA2332882A1 A process for producing an iron-dextran compound
06/02/2000CA2291453A1 Dna-constructs of blood clotting factors and p-selectin
05/2000
05/31/2000EP1003787A2 Agent for the treatment and/or prophylaxis of microcirculation disorders
05/31/2000EP1003772A1 Chemical modification of proteins to improve biocompatibility and bioactivity
05/31/2000EP1003770A1 Secreted proteins and polynucleotides encoding them
05/31/2000EP1003763A1 83 human secreted proteins
1 ... 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 ... 671